Celldex Therapeutics Stock News

MetLife Investment Management LLC acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 14,507 shares of the biopharmaceutical companys stock, valued at approximately $485,000. A number of other large investors []

MetLife Investment Management LLC acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 14,507 shares of the biopharmaceutical companys stock, valued at approximately $485,000. A number of other hedge funds also recently made []

Celldex Therapeutics, Inc. (NASDAQ:CLDX) SVP Diane C. Young sold 4,600 shares of the business’s stock in a transaction dated Friday, November 12th. The shares were sold at an average price of $42.94, for a total transaction of $197,524.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible […]

Related Stocks: CLDX , OCUL , NVRO , CTMX , CERS , IMTX , KROS , XFOR , AFMD , BCYC , ARCT , BBIO , CHAQ , PALI , EPIX , ECOR , SIEN , BCTX ,

Celldex Therapeutics, Inc. (NASDAQ:CLDX)s stock price traded up 4.7% on Monday . The company traded as high as $44.37 and last traded at $43.96. 3,957 shares were traded during trading, a decline of 99% from the average session volume of 652,480 shares. The stock had previously closed at $41.97. A number of brokerages have recently []

Wall Street analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to post sales of $1.39 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Celldex Therapeutics’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $3.48 million. Celldex Therapeutics reported sales of $3.79 million […]

Related Stocks: APLS , CLDX , BBIO , RCUS , IPSC , CTKB , OMGA , TENX , ZLAB , XLRN , TSHA , KYMR , MRUS , RVMD ,

HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferenc

FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graph

- Rapid and sustained improvement in urticaria control after single dose of CDX-0159 - - Greatly improved patient quality of life and reduced disease impact - - Data further support 95% complete respo

HAMPTON, N.J., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1

Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.

HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of